Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children by Aleebrahim-Dehkordi, Elahe et al.
Journal of Pediatric Nursing 56 (2021) 70–79
Contents lists available at ScienceDirect
Journal of Pediatric Nursing
j ourna l homepage: www.ped ia t r i cnurs ing.orgHuman Coronaviruses SARS-CoV,MERS-CoV, and SARS-CoV-2 in ChildrenElahe Aleebrahim-Dehkordi a,b, Faezeh Soveyzi a,c, Niloofar Deravi a,d, Zahra Rabbani a,c,
Amene Saghazadeh a,e, Nima Rezaei e,f,g,⁎,1
a Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Iran
b Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Iran
c School of Medicine, Tehran University of Medical Sciences, Iran
d Student's Research Committee, School of medicine, Shahid Beheshti University of Medical Sciences, Iran
e Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Iran
f Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Iran
g Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran⁎ Corresponding author at: Research Center for Immuno
Center, Tehran University of Medical Sciences, Tehran, Ira
E-mail address: rezaei_nima@tums.ac.ir (N. Rezaei).
1 Mailing address: Children's Medical Center Hospita
Tehran 14,194, Iran
https://doi.org/10.1016/j.pedn.2020.10.020
0882-5963/© 2020 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 May 2020
Revised 7 September 2020








ChildrenThe novel coronavirus, known as 2019-nCoV or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused an epidemicwith highmortality andmorbidity since December 2019, inWuhan, China. The infection
has now been transmitted to more than 210 countries worldwide and causedmore than 200,000 deaths. Similar
to other coronaviruses such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and theMiddle East
Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 appears to less commonly affect pediatrics and to
cause less severe disease along with fewer symptoms compared to adults. Available data suggest that the pedi-
atric population is just as likely as adults to become infectedwith SARS-CoV-2. However, theymay be asymptotic
or have milder symptoms than adults; they can be potential carriers of the disease. This article reviews the
present understanding of SARS-CoV-2 infection in the pediatric age group in comparison with MERS-CoV and
SARS-CoV.
© 2020 Elsevier Inc. All rights reserved.Introduction
Coronaviruses (CoVs) are single-stranded positive-sense RNA vi-
ruses belonging to the family Coronaviridae and the order Nidovirales
(Chen, Liu, & Guo, 2020; Wu et al., 2020a; Yang et al., 2020). These
enveloped viruses possess a non-segmented genome and have the po-
tential to cause respiratory diseases, with varying severity in humans
and animals (Guy, Breslin, Breuhaus, Vivrette, & Smith, 2000). They
fall into the four genera: alpha, beta, gamma, and delta. Both alpha
and beta coronaviruses can infect humans (hCoVs) (Zhu et al., 2020).
Of these, three beta CoVs have been epidemic causes: SARS-CoV,
MERS-CoV, and SARS-CoV-2.
Severe acute respiratory syndrome (SARS) develops as a sudden
onset unusual type of viral pneumonia. The 2002–2003 SARS outbreak
started from one of the southern states of China and spread to more
than 30 East Asian countries. The incubation period takes between 2deficiencies, Children'sMedical
n.
l, Dr. Qarib St, Keshavarz Blvd,and 7 days up to 10 days. Cold symptoms, such as low-grade fever,mus-
cle aches, and dry cough, are thefirst signs of illness. Theremight be uni-
lateral or bilateral pneumonia in chest imaging. Lymphopenia, hypoxia,
and elevated creatine phosphokinase (CPK) and lactate dehydrogenase
(LDH) (Alsaad et al., 2018; Luk, Li, Fung, Lau, & Woo, 2019; Momattin,
Al-Ali, & Al-Tawfiq, 2019) commonly occur in patients with SARS-CoV.
The 2012 MERS coronavirus (MERS-CoV) outbreak is associated
with a wide range of diseases, from mild fever and respiratory symp-
toms to upper respiratory tract infection, diarrhea, weakness, and leth-
argy. In severe cases, it can lead to progressive infection of the lungs and
respiratory failure, renal failure, or multiple organ failure (Bosch, Raj, &
Haagmans, 2013; Drosten et al., 2014; Widagdo, Okba, Stalin Raj, &
Haagmans, 2017).
COVID-19 is a recently emerged coronavirus disease first reported
from Wuhan, China. Due to the worldwide spread of the disease, the
World Health Organization has declared COVID-19 a global epidemic
on March 21 (Hanaei & Rezaei, 2020; Huang et al., 2020; Hui et al.,
2020). The causative pathogen of COVID-19 shares structural similari-
ties with that of SARS and therefore has adopted the name SARS-CoV-
2. Pneumonia is the most common manifestation of COVID-19 in the
early stages, characterized by fever, cough, shortness of breath, and bi-
lateral infiltration in chest imaging (Lotfi & Rezaei, 2020). Moreover,
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(Huang et al., 2020).
Children are differently affected by COVID-19. Compared to adults,
children are more asymptomatic and develop a severe form of COVID-
19 at an incomparably lower rate (Rezaei, 2020a; Shen et al., 2020). De-
spite this, children are generally one of the most susceptible groups to
infectious diseases of viral origin. Mainly related to the subject is the re-
cently reported development of a multi-system inflammatory syn-
drome in children (MIS-C) affected by COVID-19. This review mainly
focuses on the clinical manifestations of the MERS, SARS, and COVID-
19 and, in the meantime, aims to compare these three hCoVs in terms
of prognosis, epidemiology, prevention, transmission, and treatment
in children.
Epidemiology of SARS, MERS, and COVID-19
In the last two decades, the world has faced three epidemics caused
by coronaviruses, resulting in significant global health concerns
(Guarner, 2020).
In 2002–2003, SARS-CoV emerged in Guangdong, China. It spread
rapidly to other areas and countries, including Hong Kong, China's par-
ticular administrative area, Singapore, Vietnam, and Canada (Mao, Lin,
Weng, & Chen, 2020). After having infected more than 8000 people
and resulting in 774 deaths with a mortality rate calculated at 9.5%,
the latest patient diagnosed with SARS-CoV occurred in September
2003 (Guarner, 2020). The first pediatric patients with SARS-CoV were
hospital staff contacts (Li & Ng, 2005a). Stockman et al. (Stockman
et al., 2007). state that of the 135 pediatric caseswith SARS documented
in the six publications, 80 had laboratory-confirmed SARS, and 27
existed in the SARS-affected regions (3%). There was no known source
of SARS in less than 2% of pediatric patients.
In 2012,MERS-CoV first happened in Saudi Arabia. To date, most pa-
tients with MERS-C0V have occurred in or nearby the Arabian Penin-
sula. Whereas a low reproduction number of about 1 indicates that
each patient with MERS-CoV transfers the disease to one other individ-
ual only, models estimate an R0 of 4 for SARS-CoV that corresponds to
relatively higher transmissibility of this virus (Guarner, 2020;
Schwartz & Graham, 2020). However, as compared to SARS-CoV,
MERS-CoV is more deadly, with the death rate of about 35%.
There are at least 31 pediatric patients with MERS-CoV reported to
WHO from June 2012 to April 19, 2016. The mean age of the patients
was 9.8 years. More than 80% of pediatric patients with MERS-CoV reg-
istered in Saudi Arabia, and other cases were reported in Korea, Jordan,
and the United Arab Emirates (Bartenfeld, Griese, Uyeki, Gerber, &
Peacock, 2017a).
In December 2019, the novel coronavirus disease (COVID-19) was
recognized in Wuhan, China, in some patients with an unknown form
of viral pneumonia, along with a common history of being in the
Huanan seafood market (Peeri et al., 2020). By March 22, the new coro-
navirus pandemic has been spread to over 185 countries fromChina and
appears not to be more fatal than other similar viruses, such as MERS
and SARS (Andersen, Rambaut, Lipkin, Holmes, & Garry, 2020; Pal &
Bhansali, 2020). The director-general of the WHO, Tedros Adhanom
Ghebreyesus, at a meeting on February 17, stated that over 80% of
cases with COVID-19 have “mild disease and will recover”, and in 2%
of reported patients, it appears to be fatal (Mahase, 2020). Although
the case fatality rate is lower in COVID-19 infected individuals, COVID-
19 has resulted in about 3 million confirmed cases as well as more
than 200,000 deaths by April 26, 2020. It forms a contrast with SARS
and MERS that were totally accounted for less than 2000 deaths
(1632). During the pandemic of COVID-19, the older population, people
with comorbid conditions, such as cardiovascular diseases and cancer,
and individuals with a certain genetic background appear as the most
vulnerable populations (Ahmadi, Saffarzadeh, Habibi, Hajiesmaeili, &
Rezaei, 2020; Darbeheshti & Rezaei, 2020; Shamshirian & Rezaei,
2020; Yousefzadegan & Rezaei, 2020). In the early stages of the71COVID-19 epidemic, pediatric SARS-CoV-2 infected individuals ap-
peared infrequent. Therefore, the pediatric age group is not yet consid-
ered at high risk of this disease. However, the pediatric population
infected by SARS-CoV-2 was gradually increased in line with the in-
crease of familial clusters (Pal & Bhansali, 2020). By February 11, 2020,
the Chinese Centers for Diseases Control and Prevention has reported
44,672 confirmed SARS-CoV-2 infected cases, 549 cases (1.2%) of
whom were 10–19 years old and 416 cases (0.9%) of whom were
0–10 years old. Of these infected children, 134 cases had clinical records
(今井由美子, 2020). There have been two reported deaths in the pediat-
ric age group, who tested positive for SARS-CoV-2 infection in China;
however, no deaths have been reported in the published papers from
other countries (Sinha et al., 2020). Furthermore, a cohort of 31 patients
(under the age of 18, with 28 patients under the age of 14) who were
hospitalized with SARS-CoV-2 infection in Shenzhen city of China re-
ported that apart from some common characteristics between children
and adults, a few epidemical characteristics were found in children that
sharply differed from what was formerly known about adult patients.
Accordingly, no gender preference was revealed in the pediatric pa-
tients (Chen et al., 2020).
Clinical manifestations of SARS, MERS, and COVID-19
SARS
According to the reported results of the disease, the virus has oc-
curred in adults between 25 and 70 years. Moreover, there have been
reported a few cases in adolescents (15 years old). The latent period of
the disease is between 2 and 7 days, and sometimes up to 10 days. Dur-
ing this period, patientsmight have a low-grade fever, whichmay be ac-
companied by chills and flu-like symptoms (including rapid and high
fever, muscle pain, headache, and sore throat). After 3–7 days, lower re-
spiratory problems begin with a dry cough. It can lead to shortness of
breath, and in some cases (10–20%), blood oxygen depletion. Two clin-
ical phases characterize SARS. In the first phase, the symptoms are mild
and related to the upper part of the respiratory system (symptoms of
cold, cough, shortness of breath). In the second phase, by the invasion
of the virus to the lower respiratory system, it causes cough, shortness
of breath, and, ultimately, a decrease in blood oxygenation (Lau et al.,
2004). All of these symptoms exist in adults and children, and only
symptom severity varies between them.
According to research reports, clinical manifestations in children in-
clude a low-grade fever or no fever, fatigue, and dry cough. Also, in the
early stage of the disease, the number of white blood cells and the num-
ber of lymphocytes may decrease. Children with suspected SARS have
shown clinical manifestations, including cough, chills, fatigue, vomiting,
diarrhea, rhinorrhea, diarrhea, and respiratory distress, and laboratory
abnormalities, including leukopenia, elevated AST, elevated AST, and
lymphopenia. Laboratory results such as thrombocytopenia, lymphope-
nia, and elevation in CPK and liver transaminase levels appearedmild in
young children. Results suggest that SARS is a relatively mild and non-
specific respiratory illness in young children. The clinical features ob-
served in teenagers resemble those of adults (Bitnun et al., 2003;
Leung & Chiu, 2004).
MERS
MERS-CoV can cause a wide range of symptoms frommild fever and
respiratory symptoms (upper respiratory tract infection), diarrhea,
weakness, and lethargy, to progressive respiratory failure, renal failure,
or multiple organ failure in severe cases. The most common manifesta-
tions of the disease are fever and respiratory symptoms, and all patients
develop respiratory symptoms during their illness (Bartenfeld et al.,
2017a; Schwartz & Graham, 2020). Cases of anemia, coagulopathy,
and intravascular coagulation have also been reported in patients with
MERS-CoV. There have also been reports of increased levels of serum
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ponin, C-reactive (CRP) protein, and procalcitonin, and decreased
serum sodium and albumin levels (Das et al., 2015; Moniri, Marjani,
Tabarsi, Yadegarynia, & Nadji, 2015). The MERS-CoV virus produces
symptoms similar to SARS, but with a distinct clinical course and high
mortality rates of between 35 and 50%. The rate of death from MERS is
higher in men as well as in patients with underlying diseases. The aver-
age time from the onset of symptoms to hospitalization is approxi-
mately four days, and the average time from admission to hospital to
admission to the ICU is one day. The ICU admission period is approxi-
mately 30 days. However, death occurs, on average, 12 days after the
onset of symptoms (Mohd, Al-Tawfiq, & Memish, 2016; Omrani et al.,
2014; Scobey et al., 2013).
Furthermore, out of 701 patients with confirmedMERS-CoV, only 14
were pediatric cases (2%). Compared to adult patients, MERS-CoV in
children is less frequent and seems to be associated with less mortality
unless the patient has an underlying disease or a history of infection
with other respiratory viruses. Based on the results of the screening, it
has been found that one of the children (9-month-old child) with
MERS-CoV disease has nephrotic syndrome. Different results show
that although few cases of MERS-CoV in children have been reported,
MERS remains mainly a disease of adults.
COVID-19
According to the first study of patients with new coronavirus
(SARS-CoV-2), the incubation period of the virus was, on average,
five days, with a range between 4 and 7 days (Li et al., 2020). Accord-
ing to the present epidemiological evidence, the incubation period of
COVID-19 infections varies from 1 to 14 days, generally ranging
from 3 to 7 days. SARS-CoV-2 tends to locate and replicate in the
cells of the lower respiratory tract (Heymann & Shindo, 2020). At
the initial stage of infection with SARS-CoV-2, people have general
nonspecific symptoms such as fatigue, body aches, fever, dry cough,
nausea, and diarrhea. Also, patients may develop neurological mani-
festations, such as headach and anosmia (Jahanshahlu & Rezaei,
2020a; Saleki, Banazadeh, Saghazadeh, & Rezaei, 2020; Yazdanpanah,
Saghazadeh, & Rezaei, 2020; Zu et al., 2020).
Infected children might appear asymptomatic or present with a dry
cough, fever, and fatigue, and gastrointestinal symptoms such as diar-
rhea, abdominal discomfort, nausea, and vomiting. Most children in-
fected with SARS-CoV-2 have mild clinical manifestations. Most
children recover within 1 to 2weeks after disease onset. Fewmay prog-
ress to lower respiratory infections (Zimmermann & Curtis, 2020). Ac-
cording to the results of research on 26 children with COVID-19
infection, nine patients had no apparent clinical symptom. The most
common symptomwas fever found in 11 patients. Less common symp-
toms included cough, diarrhea, rhinorrhea, and vomiting. Few children
had lymphocytopenia and elevated alanine transaminase. According
to the chest CT scan, 11 patients showed unilateral pneumonia, and
eight patients had no pulmonary infiltration. No severe complications
such as acute respiratory syndrome and acute lung damage have oc-
curred in childrenwith COVID-19. Also, the leukocyte counts in children
were the same as in adults, and most of them appeared normal or de-
creased. Lymphocyte counts in adult patients decreased significantly
(Fathi & Rezaei, 2020), while they increased beyond the normal range
in most children with COVID-19. It might reflect the fact that children
have a higher percentage of lymphocytes that gradually decrease with
age (Lai, Shih, Ko, Tang, & Hsueh, 2020a; Li et al., 2020).
At the disease onset, some cases show fever, cough, and fatigue that
is accompanied by nasal congestion, expectoration, runny nose, head-
ache, and diarrhea. The majority of children have a low-grade fever or
no fever at all (Stockman et al., 2007). As the condition progresses, dys-
pnea, cyanosis, and other signsmay arise after typically oneweek of the
disease, along with systemic toxic signs, including restlessness or mal-
aise, decreased appetite, poor feeding, and less activity. Children's72condition might progress quickly and turn to respiratory failure,
which cannot be improved by conventional oxygen (nasal catheter,
mask) within 1–3 days. Metabolic acidosis, septic shock, irreversible
bleeding, and coagulation dysfunction can take place in such severe
cases (Hui & Sung, 2003). Xia et al. (Ng et al., 2003) reported that 7 of
20 pediatric cases had a history of acquired or congenital diseases, indi-
cating that childrenwith underlying diseases can bemore vulnerable to
COVID-19. Pediatric patients usually have a better prognosis, with an
average stay of 12.9 days in the hospital. As for adults, COVID-19 can
rapidly spread in children. However, it is more likely to remain asymp-
tomatic in children than adults (Zeng et al., 2020).
Multi-system inflammatory syndrome in children with COVID-19
Unlike adults, most children with COVID-19 have mild symptoms.
However, COVID-19 may cause an inflammatory reaction in some chil-
dren (release WFoPIaCCSm, 2020; Riphagen, Gomez, Gonzalez-
Martinez, Wilkinson, & Theocharis, 2020). In late April 2020, a group
of children was admitted to the intensive care unit for a multi-system
inflammatory disease. It appeared that the disease could be related to
COVID-19. Also, there were eight children from England, in whom ex-
cessive hyperinflammatory shock was observed (Riphagen et al.,
2020) and COVID-19 related antibodies were present as well (Abrams
et al., 2020). The so-called multi-system inflammatory syndrome in
children (MIS-C) is very similar to a type of childhood disease known
as Kawasaki disease. Kawasaki disease causes inflammation in the
blood vessel walls (Prevention CfDCa, 2020; Verdoni et al., 2020). Coro-
nary artery aneurysm is a major complication of Kawasaki disease. The
diagnosis is based on the persistent presence of symptoms such as ec-
zema, lymphadenopathy, fever, conjunctival injection, and changes in
the mucous membranes and organs (Dietz et al., 2017; McCrindle
et al., 2017). Examination of the clinical and laboratory characteristics
of MIS-C shows that the syndrome is distinct from Kawasaki's disease.
Children with MIS-C are older and systemic inflammation is more se-
vere in them, and they have more myocardial damage than patients
with Kawasaki's disease (Whittaker et al., 2020). Children with MIS-C
show both the symptoms of COVID-19 and toxic shock syndrome
(TSS) and Kawasaki disease (Prevention CfDCa, 2020; (PICS) PICS,
2020). MIS-C can affect different parts of the including the heart,
lungs, kidneys, brain, skin, eyes, or gastrointestinal tract. Children with
MIS-C mostly have abdominal pain or sometimes diarrhea, neck pain,
rash, bloodshot eyes, and vomiting. Theymay also experience excessive
fatigue (Network CHA, 2020; Toubiana et al., 2020). Cases ofMIS-C have
been reported in several countries (Bahrami, Vafapour, Moazzami, &
Rezaei, 2020a; Cheung et al., 2020; Organization WH, 2020). This syn-
drome appears to occur two to four weeks after infection with COVID-
19. In countries where the prevalence of COVID-19 is high, more cases
of MIS-C have been reported in children (Control ECfDPa, 2020;
Riphagen et al., 2020). Children with this syndrome might suffer from
heart problems and need immediate care (Belhadjer et al., 2020). It is
not yet fully understood what causes MIS-C (Riphagen et al., 2020).
Virology and pathogenesis of coronaviruses
Coronaviruses (CoVs) are a family of enveloped RNA viruses (Scobey
et al., 2013) that display crown-like spikes on their surfaces
(Bermingham et al., 2012; Cowling et al., 2015; Ksiazek et al., 2003).
In particular, SARS-CoV-2 possesses a typical RNA that encodes 27 pro-
teins. The orf1ab and orf1a genes, which are located at the 5′ end of the
genome, encode the pp1ab and pp1a proteins, respectively. Together,
these two genes express 15 nonstructural proteins nsp1-nsp10 and
nsp12-nsp16. On the other hand, at the 3′ endof the genome, four struc-
tural proteins, including the spike surface protein (S), an envelope pro-
tein (E), membrane protein (M), nucleocapsid protein (E), and eight
subunit proteins, including 3a, 3b, p6, 7a, 7b, 8b, 9b, and orf 14 are
coded (Mou et al., 2013; Wu et al., 2020b).
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them can affect humans (hCoVs). Four coronaviruses, including
HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, regularly
cause respiratory infections in children and adults. Some corona-
viruses, such as SARS-CoV, MERS-CoV, and SARS-CoV-2, are highly
pathogenic to humans and can cause more severe symptoms lead-
ing to fatal cases of pneumonia (lung infection), renal failure,
multiorgan failure, and death.
HCoVs can invade the respiratory tract, intestine, and stomach and
cause respiratory and gastrointestinal diseases. Usually, coronaviruses
first infect the respiratory mucosa in the pharynx and nose and pro-
duce symptoms similar to the common Cold. coronaviruses cause
about 15% of cases of colds. Occasionally, colds that coronaviruses
cause can progress to infantile bronchitis, ear infections, or exacerba-
tion of asthma in children and adolescents, and even pneumonia in
adults, the elderly, and people with pre-existing conditions. Symp-
toms of respiratory coronavirus infections in humans are partly similar
to those of rhinovirus infections and include nasal congestion and
restlessness.
Transmission and source of infection
SARS-CoV and MERS-CoV can be transmitted through the fomite
route, aerosol transmission, and droplet transmission (Jahanshahlu &
Rezaei, 2020b; Li & Ng, 2005b; Perlman, 2020; Zumla, Hui, &
Perlman, 2015a). Person-to-person transmission of MERS-CoV occurs
by large droplets (Zumla et al., 2015a). People who have exposure
to health care centers, for example, hospitals or clinics, are at in-
creased risk for MERS infection. Some MERS outbreaks are related to
these centers as one occurred in Jeddah (Saudi Arabia), due to contact
transmission in 2014 (Zumla et al., 2015a). There are MERS cases that
at first appear as primary cases, but after more consideration, they are
confirmed as secondary because they have a history of contact with
patients (Zumla et al., 2015a). In another study by Schuster et al., pe-
diatric cases could be infected with MERS-CoV secondarily as they
were contacts of adults with MERS. Adults become infected with
MERS-CoV at the workplace or due to contact with intermediate
host animals (Schuster & Williams, 2018).
Patients infected with SARS-CoV-2 may have symptoms or be
asymptomatic. Symptomatic patients are the most contagious.
The mechanisms to spread the disease are not yet fully elucidated,
especially regarding the relative contributions of the airborne ver-
sus contact transmission routes to the COVID-19 pandemic (Zhang,
Li, Zhang, Wang, & Molina, 2020). Although contact transmission
via respiratory droplets was regarded as the main route in trans-
mitting SARS-CoV-2 virus initially (Van Doremalen et al., 2020;
Chin & Poon, 2020; (CDC) CfDCaP, 2020a; (WHO) WHO, 2020),
present experimental and epidemiological evidence has suggested
airborne transmission of the virus via respiratory aerosols as one
probable route for the spreading of COVID-19 (Liu et al., 2020;
Morawska & Milton, 2020; Prather, Wang, & Schooley, 2020; Van
Doremalen et al., 2020). A recent study of the COVID-19 pandemic
trends in New York City, Italy, and Wuhan suggested that the air-
borne transmission route dominated the spread of the disease,
and face-covering considerably shaped the trends of the outbreak
in the three mentioned epicenters (Zhang, Li, et al., 2020). There-
fore, presently, the probable transmission routes (i.e., airborne vs.
contact) for SARS-CoV-2 is a highly debated topic among the re-
search communities worldwide (Morawska & Milton, 2020).
It might also be possible for SARS-CoV-2 to be transmitted via the
oral-fecal route as well. Supporting this, the fecal samples of some pa-
tients with COVID-19 were positive for the viral nucleic acid. However,
the accuracy of this pattern of transmission needs more investigation
(Jahanshahlu & Rezaei, 2020b).
There is documented data about the vertical transmission of SARS-
CoV and MERS-CoV (Jahanshahlu & Rezaei, 2020b; Li & Ng, 2005b). A73mother with SARS-CoV is at increased risk for complications such
as spontaneous miscarriage, intrauterine growth retardation, pre-
term labor, and coagulopathy problems (Li & Ng, 2005b; Mardani &
Pourkaveh, 2020). The data from six newborns born from mothers
with COVID-19 showed that samples fromamnioticfluid and the umbil-
ical cord lacked SARS-CoV-2 RNA. Also, the neonatal pharynx sample
and mother breastmilk were negative for the nuclear acid of COVID-19
(Jahanshahlu & Rezaei, 2020b). The results of another study in china
on nine mothers who had COVID-19 associated pneumonia were simi-
lar to the previous one, and there was no virus detected in all samples.
The Apgar score of nine neonates was high, and there were no signs of
asphyxia in them (Mardani & Pourkaveh, 2020). The current evidence
is not enough to conclude that SARS-CoV-2 can be transmitted from
an infected mother to her fetus (Favre et al., 2020; Jahanshahlu &
Rezaei, 2020b;Mirbeyk&Rezaei, 2020). Because theperinatal transmis-
sion is suspicious, pregnant women who have a history of travel to af-
fected areas or have a history of exposure to infected patients are
recommended to be tested for COVID-19, even if they are asymptomatic
(Favre et al., 2020).
The outbreak of SARS-CoV is related to wildlife (Daszak, Olival, & Li,
2020). The source ofMERS-CoV infectionsmay be related to camels. The
origin of the novel coronavirus is not completely clear, but a zoonotic or-
igin of the disease is well-documented. The first confirmed cases of
COVID-19were related tomarkets that sell seafood, themeat ofwild an-
imals (Daszak et al., 2020), snakes, and other animals like livestock an-
imals and live rabbits too. Furthermore, high similarities between the
SARS-CoV-2 and bat coronaviruses support the bat origin of SARS-
CoV-2 (Perlman, 2020).
Diagnosis
First of all, the history of exposure to infected patients or travel to
the affected areas and laboratory data such as procalcitonin (PCT),
complete blood count, and C-reactive protein can help us to diagnose
this infection (Jahanshahlu & Rezaei, 2020b). A very advantageous in-
strument for distinguishing SARS infected children from the others is
real-time reverse transcription-polymerase chain reaction (RT-PCR).
RT-PCR is also used for MERS-CoV nucleic acid detection, too
(Schuster & Williams, 2018). It takes a few hours for the test to
count the RNA viruses in the serum (Li & Ng, 2005b). However, the
value of conventional RT-PCR decreases along the first week of the
SARS-COV infection (Li & Ng, 2005b), and its sensitivity is not accept-
able. In a study of pediatric cases with SARS, conventional RT-PCR of
fecal and nasopharyngeal specimens could detect less than 50% of
real patients (Li & Ng, 2005b). Laboratory findings of SARS-COV in
children include increased lactate dehydrogenase (LDH), decreased
neutrophil count, and elevated creatinine phosphokinase (CPK) (Li &
Ng, 2005b). Incomplete airspace filling at the edge of the lung indi-
cates the SARS-CoV infection.
Nowadays, the nucleic acid test is the gold standard for the diagno-
sis of COVID-19 (Jahanshahlu & Rezaei, 2020b). Among the specimens
taken for the diagnosis of COVID-19, the most convenient one is naso-
pharyngeal swab, with the sensitivity rate close to 50% and less
(Jahanshahlu & Rezaei, 2020b). Lower respiratory tract secretions
such as bronchoalveolar lavage fluid that contains a high amount of
viral RNA are more valid specimens for the detection of the novel co-
ronavirus (Jahanshahlu & Rezaei, 2020b; Zumla et al., 2015a). Also, the
pharyngeal swab was used one day after labor for an asymptomatic
newborn infected with COVID-19 (). Some children who tested nega-
tive for COVID-19 might be infected with this virus and could spread
the virus among other people, so the test should be repeated for
them (). Imaging data could help us with the diagnosis of COVID-19
in children. High resolution computed tomography (HRCT) can be
more helpful than a chest X-ray in this regard. Imaging abnormalities
related to COVID-19 include ground-glass opacities (GGO) and
peribronchial thickening (Li & Ng, 2005b).
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Among children affected by SARS-CoV and MERS-CoV, females are
infected slightly more than males (Al-Sehaibany, 2017; Chang et al.,
2004; Hon et al., 2003; Memish et al., 2014; Thabet, Chehab, Bafaqih,
& Al, 2015). Most of the children with SARS did not have underlying
conditions except for two children reported with epilepsy and sponta-
neous pneumothorax. In contrast, childrenwithMERS showed underly-
ing diseases, like renal failure, cystic fibrosis, and Down syndrome. Also,
coinfection with influenza is reported in children with MERS
(Bartenfeld, Griese, Uyeki, Gerber, & Peacock, 2017b; Chang et al.,
2004; Memish et al., 2014; Thabet et al., 2015). Searching the exposure
history of contaminated children, the majority of them had at least one
of the history of traveling to endemic areas, contact with health care
workers, household contact, or experiencing community outbreaks in
14 days before the initiation of the disease (Bartenfeld et al., 2017b;
Chang et al., 2004; Hon et al., 2003; Memish et al., 2014; Ng, Leung,
Chiu, Wong, & Hon, 2004; Thabet et al., 2015).
Previously it was thought that among children with COVID-19, fe-
male ones are affected more than male ones. However, recent reports
show the reverse, raising the need to further surveys to investigate
the issue. The manifestations of COVID-19 vary from asymptomatic,
mild, and moderate to severe and critical ones. Some of the underlying
conditions like malnutrition, congenital heart disease, and hydronep-
hrosis might make children susceptible to severe COVID-19. Moreover,
children may develop respiratory coinfections like mycoplasma pneu-
monia, influenza virus, Epstein-Barr virus, respiratory syncytial virus,
parainfluenza virus, and adenovirus (Lu & Shi, 2020; Shen & Yang,
2020; Wong, Leo, & Tan, 2020; Xia et al., 2020; Zhang et al., 2020).
Possible sources of infection in children affected by COVID-19 in-
clude contact with infected adults (with the history of travel to endemic
areas or contact with a person living in such areas), having at least one
family member infected with COVID-19, presence in population clus-
ters, living in or traveling to affected areas, having visited a hospital or
a history of contact with animals (Cai et al., 2020; Chen et al., 2020;
Shen & Yang, 2020; Wang, Wang, Chen, & Qin, 2020; Yang, Liu, Li, &
Disease, 2019). Vertical transmission from infected mothers needs fur-
ther investigations to be clarified as a predisposing factor (Chen et al.,
2020; Liu et al., 2020; Lu & Shi, 2020; Zhu et al., 2020).
Prevention
In a case-control study in five hospitals in Hong Kong, Seto et al. re-
vealed that the use of masks could markedly reduce the risk of SARS-
CoV infection among healthcare workers. Among surveyed noninfected
staff members who wore masks, 15.3% of them were reported to have
used paper masks, 30.7% surgical masks, and 54.4%, N95masks. Contact
and droplet precautions alone were shown to be sufficient to protect
against SARS-CoV infection. Additionally, no marked difference was re-
vealed between the surgical and N95 masks (Seto et al., 2003). In its
May 2003 interim Domestic Guidance on the use of respirators to
prevent transmission of SARS, the US Centers for Disease Control and
Prevention (CDC) reported that disposable N95 respirators are suffi-
cient for routine airborne isolation precautions. However, in case N95
masks were not available, a surgical mask should be worn ((CDC)
CfDCaP, 2003). Regarding SARS, children with mild symptoms and pa-
tients with the common flu-like manifestations of the disease at the ini-
tial phase could transmit the infection,which demanded early detection
and separation of these children (Tian et al., 2020; Yang et al., 2019).
Also, suspension of schools, contact tracing, preparing wards with neg-
ative pressure ventilation for the infected patients, and practicing hy-
giene preventions by schools were recommended (Leung, Wong, Hon,
& Fok, 2003; Li & Ng, 2005c).
Additionally, WHO supported the use of surgical (procedure) masks
when caring for suspects with either possible or confirmed MERS-CoV
infection as well as particulate respirators in case of aerosol-generating74procedures ((WHO)WHO, 2013). CDC also supported the use of partic-
ulate respirators additional to airborne precautions for all MERS patient
care activities ((CDC) CfDCaP, 2014). For MERS prevention, besides
points stated for SARS, cooking or pasteurization of camel products
and avoidance of contact with camels and their products, touching
nose, eyes, and mouth while working with camels were considered
(Al-Tawfiq & Memish, 2015; Disease-a-month : DM, 2017; Zumla, Hui,
& Perlman, 2015b).
COVID-19 has now turned into an endemic matter, which is spread-
ing rapidly. In order to break this cascade of distribution, some preven-
tive measures are needed both in society and healthcare levels. Some of
the precautions needed to be considered by the healthcare system in-
clude early identification and isolation of the infected patients in
wardswith appropriate environmental ventilation, isolation of the neo-
nates born from infected mothers and examining them for COVID-19,
training the health care personnel to use adequate personal protective
equipment, and optimization of medical intervention and personnel
visiting in order to reduce nosocomial transmission. Besides, carrying
patients with special vehicles and by fully protected staffs, standard
elimination of the dischargeable productions of the patients, and isola-
tion of the infantswith the underlying disease early after delivery is nec-
essary to be considered. For the public preventivemeasures, training via
trustable sources, travel controlling and inhibition of the entry from en-
demic areas, the boundary of the population clusters and canceling the
family unions, protection of the susceptible population, and probing the
children of the families with at least one contaminated member should
be regarded. Also, people should be trained to practice hand hygiene
and surface cleaning, use protective outfits when visiting and taking
care of the patients, control the source of infection and the route of
transmission, and use protective tools while having contact with ani-
mals. It is required to disinfect the toys and provide specific protective
equipment for children younger than 12 months (Chen, Fu, et al.,
2020; Lai, Shih, Ko, Tang, & Hsueh, 2020b; Liu, Wang, et al., 2020; Lu &
Shi, 2020; Shen & Yang, 2020; Wang et al., 2020; Wei et al., 2020;
Wong et al., 2020; Xu et al., 2020; Yang, Liu, et al., 2020). Furthermore,
due to the immunologic and phylogenetic similarities between SARS-
CoV, MERS-CoV, and SARS-CoV-2, infection control precautions may
be extrapolated from the previous experience with MERS and SARS
(Jabbari, Jabbari, Ebrahimi, & Rezaei, 2020). Moreover, Esposito et al.
stated that the common use of facial masks is necessary for people's ev-
eryday outdoor lives. Masks of different sizes capable of perfectly
adapting to the face should be available. Moreover, it is crucial that by
strong parental work as well as school lessons on this issue, child coop-
eration is obtained, and thus, the use of masks in children is preceded
(Esposito & Principi, 2020). However, protecting healthy children with
mask faces difficulties. Children younger than two years of age are rec-
ommended not towear any type ofmasks since their very small airways
might then struggle to breathe. Furthermore, since without assistance,
theymay be unable to remove themasks, they can be at high risk of suf-
focation ((CDC) CfDCaP, 2020b). Surgical masks suitable for children
from 3 to 12 years old are now widely marketed, and they can also be
prepared at home from commonly available materials at low cost, ac-
cording to the US Centers for Disease Prevention and Control
(Balasubramanian, Rao, Goenka, Roderick, & Ramanan, 2020).
During theprocess of delivery in the infectedmothers,merely essen-
tial staff with appropriate personal protective equipment should be
present, and themother has towearmasks andmaintain hand hygiene.
The resuscitation personnel should keep a distance of at least 2 m be-
tween the newborn and the mother. After the delivery, the mother
should be encouraged to breastfeeding while wearing a mask
(Balasubramanian et al., 2020). Tele triaging patients and quarantines
are important strategies to be provided by the health care system
(Moazzami, Razavi-Khorasani, Dooghaie Moghadam, Farokhi, & Rezaei,
2020). People should be educated to practice appropriate interpersonal
distance and to restrain themselves from touching their eyes andmouth
with unwashed hands (Adhikari et al., 2020; Unni, 2020).
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There is no specific antiviral drug to treat COVID-19, SARS, and
MERS. The primary treatment of these conditions involves the correc-
tion of electrolyte and acid-base imbalance and oxygenation. In this
context, there are no adequate clinical trials in pediatric cases. The treat-
ment protocols for children are, therefore, similar to those for adults
(Jahanshahlu & Rezaei, 2020b).
Studies recommend a combination of drug therapy for patients with
MERS infection. This combination therapy consists of a nucleoside in-
hibitor named Ribavirin and subcutaneous interferons (IFNs) such as
IFNα-2b and IFNβ. It could decrease pulmonary damage and boost the
14-day survival but failed to improve 28-day survival (Schuster &
Williams, 2018; Zumla et al., 2015a). Broad-spectrum antibiotics were
considered for children with SARS who had symptoms of fever and
pneumonia. In phase 2 of SARS infection, systemic corticosteroids
might be administrated to regulate the immune system and reduce
lung damage. Intravenous methylprednisolone pulse therapy was asso-
ciatedwith better clinical and radiological outcomes in childrenwith se-
vere SARS infection (Li & Ng, 2005b).
Corticosteroid therapy is also used in patients with severe COVID-19
(; Saghazadeh & Rezaei, 2020a), even though the incorrect use of broad-
spectrum antibiotics and corticosteroids could increase the mortality
rate in adults with COVID-19. However, patients with severe COVID-
19 disease might develop hyper inflammation and a cytokine storm
(Bahrami, Vafapour, Moazzami, & Rezaei, 2020b; Nasab, Saghazadeh,
& Rezaei, 2020; Rokni, Hamblin, & Rezaei, 2020; Saghazadeh & Rezaei,
2020b; Yazdanpanah, Hamblin, & Rezaei, 2020). Interestingly, COVID-
19 seems to happen and become severe in peoplewith primary immune
deficiency disorders less than in the general population (Ahanchian
et al., 2020; Babaha & Rezaei, 2020). This suggests the role of the
immune system in contributing to COVID-19 (Yazdanpanah, Hamblin,
& Rezaei, 2020) and therefore indicates the diagnosis and treatment
of hyperinflammatory state as crucial for reducing mortality. Hence
for this subgroup, immunosuppression using corticosteroids, Janus
kinase (JAK) inhibitors, selective cytokine blockade, and intravenous
immunoglobulin can be considered (Jahanshahlu & Rezaei, 2020b;
Mansourabadi, Sadeghalvad, Mohammadi-Motlagh, & Rezaei, 2020;
Mehta et al., 2020; Pashaei & Rezaei, 2020; Pourahmad, Moazzami, &
Rezaei, 2020; Ritchie & Singanayagam, 2020).
Moreover, a recent study investigated the role of extracorporeal
membrane oxygenation (ECMO) in themanagement of severely ill indi-
viduals with confirmed COVID-19 who develop acute respiratory and
cardiac compromise refractory to conventional therapies. This analysis
of 32 COVID-19 patientswith severe pulmonary compromise supported
with ECMO stated that ECMO could be useful in salvaging critically ill
participants with COVID-19. However, further studies are necessary to
enhance our understanding of the role of ECMO in patients with
COVID-19 and ARDS (Jacobs et al., 2020).
Except in critical cases, childrenwith COVID-19 did not require anti-
viral drug treatment because they could be recovered on their own ().
The administration of Remdesivir seems to have positive effects
(Mohamed, Yazdanpanah, Saghazadeh, & Rezaei, 2020), but its efficacy
has not been proven for children.
Current concerns on pediatric COVID-19
Debate on the epidemiology of COVID-19 in children
In the early stages of COVID-19, it was thought that children were
rarely affected by the virus (Wu &McGoogan, 2020). However, current
reports suggest that children are just as affected as adults but with
milder symptoms, lower disease severity, and lower mortality (Bi
et al., 2020; Zimmermann & Curtis, 2020). SARS-CoV-2 is transmitted
through human-to-human contact and occurs within both family and
social relationships (Lotfi, Hamblin, & Rezaei, 2020). It is difficult for75children, especially toddlers, to follow the principles of hygiene, and
baby carriers are expected to transmit the COVID-19. The lack of aware-
ness of the disease in affected children is another possible explanation
for the high rate of disease transmission (Fan et al., 2020). Children
are likely to expose themselves to other children, friends, and family
members, and this directly correlates with the person to person trans-
mission of COVID-19 (Phan et al., 2020).
PCR limitation and antibody detection
There are many limitations to the PCR method, such as high rates of
peoplewith false-negative tests. It also takes a long time for the PCR test
to tell us the result, so rapid tests are needed to prevent the spread of the
coronavirus from suspect cases to the general population (Basiri et al.,
2020).
Serological testing based on antibodies can be used for patients with
asymptomatic infection. Recently studies reported the development of
rapid antibody tests with the use of nucleocapsid and spike proteins
as antigens. These tests work based on the detection of both IgG and
IgM antibodies in whole blood or serum samples simultaneously. They
might take about 15min and have reasonable specificity and sensitivity
(GeurtsvanKessel et al., 2020; Li et al., 2020; Long et al., 2020).
Asymptomatic infection in children
6.7% of children get the infection severely, and the rest is known as
asymptomatic carriers. It is, therefore, essential to identify asymptom-
atic or mild infected children to prevent the virus from spreading
(Tezer & Bedir, 2020). Based on the current evidence, viral load in symp-
tomatic cases and asymptomatic carriers is approximately the same.
The late identification of asymptomatic carriers makes them a source
of uncontrollable infection (Yu & Yang, 2020). As a result, paying atten-
tion to children who get the infection less severe than adults and iden-
tifying early asymptomatic ones will help prevent the transmission of
the virus (Ciuca, 2020).
Social-emotional functioning in children during the pandemic
According to the recommendations of the WHO, it is better not to
separate children from their families during this pandemic and ask chil-
dren to speak about their emotions to give them a sense of calm. There
are simple but effective ways to entertain children, such as painting or
playing with them. Depending on the age of the children, it is appropri-
ate to provide them with useful disease-related information to the ex-
tent of their understanding because they will become more curious
during the crisis and ask more questions of their parents (WHO,
2020). According to the behavioral research conducted on children
aged between 3 and 18 in Shaanxi, clinginess is the most prevalent
problem, especially in younger children (3–6 years old). Since children
in epidemic areas suffer from fear, using media as a hobby could help
them to forget about their bad feelings (Jiao et al., 2020).
Conclusion
In the past two decades, the world has witnessed three outbreaks
caused by coronaviruses: SARS-CoV, MERS-CoV, and SARS-CoV-2. Stud-
ies propose a zoonotic origin for these three coronaviruses. These path-
ogens can affect pediatrics as well as adults. However, the majority of
the children showmild manifestations except for the ones with under-
lying conditions. Among pediatrics, the main signs and symptoms in-
clude fever, respiratory symptoms, and other flu-like manifestations.
Nucleic acid tests and imaging techniques are used for the diagnosis. Se-
rological tests have reasonable specificity and sensitivity and can also be
used for diagnosis of a new infection, recent infection, and re-infection
as well (Jabbari & Rezaei, 2020). Public education for practicing hygiene
and contact avoidance with infected patients, as well as isolation of the
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drug treatment has been discovered up to date, supportive and symp-
tom alleviating treatments are the principal therapies. However, regen-
erative medicine and targeted therapies pose potentials to the COVID-
19 (Basiri et al., 2020; Fathi & Rezaei, 2020; Mansourabadi et al., 2020;
Pashaei & Rezaei, 2020; Rabiee, Rabiee, Bagherzadeh, & Rezaei, 2020;
Rezaei, 2020b; Sharifkashani et al., 2020). The potentials need testing
at large, and this would be well-achieved when all collaborate (Kafieh
et al., 2020; Mohamed et al., 2020; Momtazmanesh et al., 2020;
Moradian et al., 2020; Rzymski et al., 2020).
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